Kalvista Pharmaceuticals News and Activities

Presence

KalVista Pharmaceuticals develops medicines for rare diseases. Its main products are oral and injectable treatments for hereditary angioedema and related conditions, serving patients, healthcare providers, and specialty care partners.

Kalvista Pharmaceuticals products and services overview:

Rare disease treatments
Hereditary angioedema drugs
Oral medicines
Injectable therapies
Drug development

Revenue: ~$0 million

Employees: 160

Headquarters: Cambridge, United States (USA)

Kalvista Pharmaceuticals is owned by Chiesi. Chiesi has a direct presence in 13 countries.

Chiesi has 15 subsidiaries including Amryt Pharma, Chiesi Central Eastern Europe and Chiesi Czech & Slovakia.

They are in:

Pharmaceuticals94%
Biotechnology6%

Acquisition, funding and merger involving Chiesi.

Chiesi has announced the acquisition of Kalvista Pharmaceuticals (posted on June 18 2026).
Kalvista Pharmaceuticals, listed under ticker KALV, has been delisted. (posted on June 15 2026).
Chiesi has acquired Kalvista Pharmaceuticals (posted on June 11 2026).

Executives

View the org chart displaying its 19 main executives

Most searched biographies at Kalvista Pharmaceuticals

Popular executive movements at Kalvista Pharmaceuticals

John Hess, who was Senior Vice President, Americas, Chiesi, is promoted to Chairman of the Board, President and General Manager (posted on June 15 2026).
Edward Unkart, Director, has left the company (posted on June 15 2026).
Pat Treanor, Director, has left the company (posted on June 15 2026).

Click here to view some more movements at Kalvista Pharmaceuticals

Popular executive movements at Chiesi

Maria Paola Chiesi, who was Vice Chairman of the Board, is promoted to Chairman of the Board (posted on May 20 2026).
Alessandro Chiesi who was Chairman of the Board, becomes Vice Chairman of the Board (posted on May 20 2026).
Jean-Marc Bellemin who is Executive Vice President Group, Chief Financial Officer, will become Interim Chief Executive Officer and Executive Vice President Group, Chief Financial Officer on May 6, 2026 (posted on April 24 2026).

Click here to view some more movements at Chiesi

Create your alert
to follow the executive moves at Kalvista Pharmaceuticals.